Inspire Medical Systems Q2 2026 revenue fell 7.6% to $200.6M, missing estimates as reimbursement challenges persist. Adjusted EPS at $0.14. Guidance revised down.
Inspire Medical Systems, Inc. reported Q2 2026 revenue of $200.6 million, down 7.6% year-over-year and below the consensus estimate of $207.8 million. The revenue decrease comes as the company faces ongoing coding and reimbursement disruptions, which management predicts will continue to impact performance in the second half of the year.
Key Takeaways
- Revenue decreased 7.6% to $200.6 million, reflecting ongoing coding and reimbursement challenges.
- Adjusted diluted EPS was $0.14, missing the consensus of $0.15, while diluted EPS was reported at $0.01.
- Project Horizon aims to create $30 million of annualized growth investment capacity by optimizing resources and improving patient flow.
- Guidance update: Revenue outlook revised to $835 million to $875 million, reflecting coding disruptions and ongoing market challenges.
- Operating cash flow improved to $23.2 million for the quarter, indicating better working capital management despite revenue pressures.
Revenue Decline Reflects Coding Challenges
In Q2 2026, Inspire Medical Systems experienced a revenue decline of 7.6% year-over-year, down from $216.2 million in the same quarter last year. This decline is attributed primarily to ongoing disruptions related to coding and reimbursement, particularly impacting the company's Inspire 5 procedures. The average reimbursement rate for the Inspire 5 procedure is expected to be $35,414 for 2027, a 12% increase over prior rates, but final decisions are pending from CMS, creating uncertainty.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $200.6M | -7.6% | N/A |
| Adjusted EPS | $0.14 | N/A | N/A |
| Diluted EPS | $0.01 | N/A | N/A |
| Cash Flow | $23.2M | N/A | N/A |
Project Horizon Aims for Growth
Management launched a strategic initiative dubbed Project Horizon, aimed at creating an additional $30 million in annualized growth capacity. This initiative includes restructuring efforts to optimize the supply chain and align resources with revenue growth initiatives. The company expects to incur $20 million to $25 million in pre-tax restructuring charges as they consolidate production and streamline operations. The anticipated benefits of these changes are expected to materialize in 2027, with a focus on improving patient access and education.
Revised Guidance Reflects Caution
In relation to the ongoing challenges, Inspire revised its revenue outlook for the year to a range of $835 million to $875 million, down from previous estimates. This revision takes into account anticipated continued impacts from coding disruptions, with an estimated adverse effect of $40 million in Q2 alone. Adjusted operating margin is now expected to range from 4% to 6%, reflecting the current operating environment and restructuring efforts.
Analyst Q&A Highlights Concerns and Optimism
During the analyst Q&A, the topic of reimbursement coding was central, with management acknowledging the challenges posed by the transition to new coding requirements. An analyst from Stifel asked about the utilization trends in regions facing significant fee cuts. Management responded that ongoing education efforts are crucial, as many hospitals are adapting to minimize reductions in service levels. Additionally, they noted that centers are becoming increasingly familiar with the new coding, leading to improved authorization submissions.
Another analyst inquired about Project Horizon's impact on growth initiatives. Management clarified that the majority of the $30 million capacity would be directed towards enhancing patient flow and education, with expectations of seeing benefits in revenue growth starting in 2027.
Closing Thoughts
Inspire Medical Systems faces a pivotal moment as it navigates reimbursement challenges while launching initiatives aimed at fostering growth. The success of Project Horizon and the company's ability to adapt to changing coding landscapes will be crucial as it seeks to reinvigorate revenue growth and restore investor confidence.
This analysis is based on public earnings call materials and is not investment advice.
